Clinical Trial

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Study acronym: SALVOVAR
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.
Protocol Amendment History 2 changes
notable Trial sites expanded: 72 -> 76 locations 2026-08-05
minor Completion moved earlier: 2028-12 -> 2028-06 2026-08-05
Trial Details
NCT Number NCT06476184
Lead Sponsor ARCAGY/ GINECO GROUP
Collaborators: Horizon 2020 - European Commission
Conditions Ovarian Cancer
Enrollment 250 participants
Start Date 2024-07-30
Primary Completion 2027-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-04